5-methyl-4H-[1,2,4]triazolo[1,5-a]pyrimidine-7-thione | 34270-41-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 5-methyl-4H-[1,2,4]triazolo[1,5-a]pyrimidine-7-thione
• 英文别名: 7-Mercapto-5-methyl-s-triazolo[1,5-a]pyrimidine
• CAS: 34270-41-2
• 化学式: C₆H₆N₄S
• mdl: MFCD00227623
• 分子量: 166.206
• InChiKey: VLJHBRJKVDNXKC-UHFFFAOYSA-N

物化性质

• 熔点：
  278-279 °C (decomp)(Solv: water (7732-18-5))
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.53
• 重原子数：
  11.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  43.08
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  5-methyl-4H-[1,2,4]triazolo[1,5-a]pyrimidine-7-thione 、 3-acetoxymethyl-7-aminoceph-3-em-4-carboxylic acid 在 碳酸氢钠 作用下， 以 水 、 乙酸乙酯 、 乙腈 为溶剂， 生成 (6R,7R)-7-amino-3-[(5-methyl-s-triazolo[1,5-a]pyrimidin-7-yl)thiomethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  Cephalosporin derivatives

  摘要：

  本发明涉及新型头孢菌素衍生物、其制备方法、以新型头孢菌素衍生物作为活性成分的预防和/或治疗传染病的组合物，以及头孢菌素衍生物合成中的中间体化合物和其制备方法。本发明的新型头孢菌素衍生物包含紧缩杂环基团，特别是三唑嘧啶环或噻唑嘧啶环作为头孢菌素骨架的3位取代基，并且在头孢菌素骨架的7位取代基是羟肟基、烷氧基肟基或酰氧基肟基。本发明中含有上述取代基的化合物对革兰氏阴性菌和包括甲氧西林耐药金黄色葡萄球菌在内的革兰氏阳性菌具有强大的抗菌活性。这些化合物对于治疗传染病非常有用。

  公开号：

  US04888332A1

文献信息

• Silver halide photographic material
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0167168A2

  公开（公告）日：1986-01-08

  A silver halide photographic material containing at least one compound having a group which after being released from the compound by redox reaction becomes converted into a compound having the development restraining ability and which becomes further converted in the developing solution into a compound which has no substantial development restraining ability or which shows a marked decrease in such ability.

  一种含有至少一种化合物的卤化银感光材料，这种化合物含有一种基团，这种基团通过氧化还原反应从化合物中释放出来后，转化成一种具有显影抑制能力的化合物，这种化合物在显影液中进一步转化成一种没有实质性显影抑制能力或显影抑制能力明显下降的化合物。
• Cephalosporin derivatives and bactericides containing the same
  申请人：MEIJI SEIKA KAISHA LTD.

  公开号：EP0209751A2

  公开（公告）日：1987-01-28

  New cephalosporin compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are provided, which have a broad bactericidal spectrum against various pathogenic bacteria including Pseudomonas aeruginosa and are useful as bactericidal remedies for pathogenic diseases of human and animals. wherein A represent an alkanoyloxy group having 2-5 caroo atoms; a carbamoyloxy group; an azido group; or an unsut stituted or substituted pyridylthio group of a formula (1-1): (where n is 0 or an integer of 3-5; R1 and R2 may be same or different and each represent a hydrogen atom, a halogen atom, a carboxyl gorup or an optionally halogen-substituted lower alkyl group having 1-5 carbon atoms; or an unsubstituted or substituted pyridiniumthio group of a formula (I-2): (where n, R' and R2 have the same meaning as above; R3 represents linear or branched alkyl group having 1-5 carbon atoms; a halogen-substituted alkyl group, a cyclopropyl group, a cyclopropylmethyl group, an alkenyl group, an ox- ygen atom or a group of-(CH2)m-B;(m is an integer of 0-3; and B represents a hydroxyl group, an alkoxy group, an amino group, an alkyl-substituted amino group, a carboxyl group a carbamoyl group, a sulfonic acid group, a sulfonic acid amide group, a hydroxamic acid group, a cyano group, a thiol group, an alkylthio group, a methanesulfonylaminocarbonyl group or an acetamidosulfonyl group)]; or an unsubstituted or substituted pyridinium group of a formula (1-3): (where n has the same meaning as above; R4 and R5 may be same or different and each represent a hydrogen atom, a linear or branched aklyl group having 1-5 carbon atoms, a carboxyl group, a carbamoyl group, a sulfonic acid group, a sulfonic acid amide group, a linear or branched alkylthio group having 1-5 carbon atoms, a halogen-substituted alkylthio group, a cycloalkanothio group, a cycloalkanomethylthio group, a carboxyalkylthio group, a carbamoylalkylthio group, an alkoxyalkylthio group or an alkyl-substituted aminoalkylthio group); or a 5- or 6- membered heterocyclicthio or bicycloheterocyclicthio group of a formula (1-4): (where Het represents an optionally substituted thiazole, isothiazole, 1,2,3-thiadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,3,4-tetrazole, pyrimidine, 1,2,4-triazine, benzothiazole, benzimidazole, benzoxazole, 1,3,4-triazaindolidine or 2,3-dihydro-1H-idolidinium group).

  本发明提供了由下式(I)代表的新型头孢菌素化合物及其药学上可接受的盐类，它们对包括铜绿假单胞菌在内的各种病原菌具有广泛的杀菌谱，可作为人类和动物病原性疾病的杀菌剂。 其中 A 代表具有 2-5 个碳原子的烷酰氧基；氨基甲酰氧基；叠氮基；或式（1-1）的未取代或取代的吡啶硫基： (其中 n 为 0 或 3-5 的整数；R1 和 R2 可以相同或不同，各自代表氢原子、卤素原子、羧基或可选的卤素取代的具有 1-5 个碳原子的低级烷基；或式（I-2）的未取代或取代的吡啶硫基： (其中 n、R' 和 R2 的含义同上；R3 代表具有 1-5 个碳原子的直链或支链烷基；卤素取代的烷基、环丙基、环丙基甲基、烯基、氧原子或(CH2)m-B 的基团；(m 为 0-3 的整数；B代表羟基、烷氧基、氨基、烷基取代的氨基、羧基、氨基甲酰基、磺酸基、磺酸酰胺基、羟肟酸基、氰基、硫醇基、烷硫基、甲磺酰氨基羰基或乙酰胺磺酰基）]；或式（1-3）的未取代或取代的吡啶鎓基团： (其中 n 的含义同上；R4和R5可以相同或不同，各自代表氢原子、具有1-5个碳原子的直链或支链烷基、羧基、氨基甲酰基、磺酸基、磺酸酰胺基、具有1-5个碳原子的直链或支链烷硫基、卤素取代的烷硫基、环烷硫基、环烷甲基硫基、羧基烷硫基、氨基甲酰基烷硫基、烷氧基烷硫基或烷基取代的氨基烷硫基）；或式（1-4）的 5 或 6 成员杂环硫基或双环杂环硫基： (其中 Het 代表任选取代的噻唑、异噻唑、1,2,3-噻二唑、1,3,4-噻二唑、1,3,4-三唑、1,2,3,4-四唑、嘧啶、1,2,4-三嗪、苯并噻唑、苯并咪唑、苯并恶唑、1,3,4-三氮吲哚啶或 2,3-二氢-1H-idolidinium 基团)。
• Beta-Lactam compound, method for preparing the same, medicinal composition for bacterially infectious disease therapy containing the same and intermediates for synthesis of the same
  申请人：SANKEI PHARMACEUTICAL COMPANY LIMITED

  公开号：EP0254495A2

  公开（公告）日：1988-01-27

  There are disclosed a β-lactam compound represented by the formula (I): wherein R₁ and R₂ are independently a hydrogen atom or a lower alkyl group; M is a hydrogen atom, a protective group or an eliminatable group which is easily hydrolyzable in a human body; Rʹ and Rʺ are independently a hydrogen atom or a protective group; A is a mercapto group substituted by a sub­stituted or unsubstituted polycyclic nitrogen-con­taining heterocyclic ring or a group represented by the following formula (a):     -OOCNR₃R₄      (a) where R₃ and R₄ are independently a hydrogen atom or a lower alkyl group, provided that R₁ and R₂ are both hydrogen atoms, both R₃ and R₄ being hydrogen atoms are excluded, or its pharmaceutically acceptable salt, and a method for preparing the same, medicinal composition for microbism therapy containing the same and intermediates for synthesis of the same.

  本发明公开了一种β-内酰胺化合物，由式(I)表示： 其中 R₁ 和 R₂ 独立地为氢原子或低级烷基；M 为氢原子、保护基团或在人体内易水解的可消除基团；Rʹ 和 Rʺ 独立地为氢原子或保护基团；A 为被取代或未取代的多环含氮杂环取代的巯基或下式(a)所代表的基团： -OOCNR₃R₄ (a) 其中 R₃ 和 R₄ 独立地为氢原子或低级烷基、 但 R₁ 和 R₂ 均为氢原子，R₃ 和 R₄ 均为氢原子者除外、 或其药学上可接受的盐，以及制备上述物质的方法、含有上述物质的微生物治疗药物组合物和合成上述物质的中间体。
• Silver halide photographic materials
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0220746B1

  公开（公告）日：1991-12-27
• Cephalosporin derivatives, processes for producing the same and compositions containing them
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0150507B1

  公开（公告）日：1992-08-05